Cargando…
Clinical characteristics of hepatitis flares during pregnancy and postpartum in Chinese chronic hepatitis B virus carriers—a prospective cohort study of 417 cases
BACKGROUND: In China, it is common for pregnant women with a high load of hepatitis B virus (HBV) to take nucleos(t)ide analogue (NA) to prevent maternal-to-child transmission of HBV. However, the impact of NA intervention on virological and biochemical parameters in pregnant and postpartum women an...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606458/ https://www.ncbi.nlm.nih.gov/pubmed/36311697 http://dx.doi.org/10.3389/fimmu.2022.1031291 |
_version_ | 1784818301694640128 |
---|---|
author | Wang, Xiaoxiao Song, Aixin Lin, Xiao Lu, Junfeng Zheng, Sujun Ma, Lina Ren, Shan Zheng, Yanhong Chen, Xinyue |
author_facet | Wang, Xiaoxiao Song, Aixin Lin, Xiao Lu, Junfeng Zheng, Sujun Ma, Lina Ren, Shan Zheng, Yanhong Chen, Xinyue |
author_sort | Wang, Xiaoxiao |
collection | PubMed |
description | BACKGROUND: In China, it is common for pregnant women with a high load of hepatitis B virus (HBV) to take nucleos(t)ide analogue (NA) to prevent maternal-to-child transmission of HBV. However, the impact of NA intervention on virological and biochemical parameters in pregnant and postpartum women and the safety of drug cessation remain unclear. A prospective observational cohort was established in this study to analyze the clinical characteristics of hepatitis flares in pregnant and postpartum chronic HBV carriers, with or without NA intervention. METHODS: Pregnant women who were chronic HBV carriers were enrolled in this study and divided into an NA intervention group and a non-intervention group according to their preferences. Liver function, HBV DNA level, and HBV serological markers were regularly measured during pregnancy and at approximately 6 weeks, 12 weeks, 24 weeks, 36 weeks, and 48 weeks postpartum. RESULTS: A total of 417 patients were enrolled, including 303 in the NA intervention group and 114 in the non-intervention group. The incidence rates of postpartum hepatitis flares in both groups were higher than that of during pregnancy (45.7% vs 10.9%, p < 0.001; 41.2% vs 17.7%, p < 0.001). The second trimester was the peak of the incidence of flares during pregnancy and the incidence peak of postpartum flares was about 6 weeks postpartum. A total of 98% (145/148) of postpartum flares occurred within 24 weeks postpartum. After drug cessation, the incidence rate of flares was 34.1% (44/129). CONCLUSION: In pregnant chronic HBV carriers, a certain proportion of hepatitis flares occurred during pregnancy and postpartum regardless of whether NA intervention was used, and the incidence of postpartum flares (44.6%) was significantly higher than that (12.8%) of during pregnancy. The flare incidence peaked at approximately 6 weeks postpartum, which may be the time period suitable for treatment. Since 98% of postpartum flares occurred within 24 weeks postpartum, the follow-up after drug cessation should be at least 24 weeks postpartum. |
format | Online Article Text |
id | pubmed-9606458 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96064582022-10-28 Clinical characteristics of hepatitis flares during pregnancy and postpartum in Chinese chronic hepatitis B virus carriers—a prospective cohort study of 417 cases Wang, Xiaoxiao Song, Aixin Lin, Xiao Lu, Junfeng Zheng, Sujun Ma, Lina Ren, Shan Zheng, Yanhong Chen, Xinyue Front Immunol Immunology BACKGROUND: In China, it is common for pregnant women with a high load of hepatitis B virus (HBV) to take nucleos(t)ide analogue (NA) to prevent maternal-to-child transmission of HBV. However, the impact of NA intervention on virological and biochemical parameters in pregnant and postpartum women and the safety of drug cessation remain unclear. A prospective observational cohort was established in this study to analyze the clinical characteristics of hepatitis flares in pregnant and postpartum chronic HBV carriers, with or without NA intervention. METHODS: Pregnant women who were chronic HBV carriers were enrolled in this study and divided into an NA intervention group and a non-intervention group according to their preferences. Liver function, HBV DNA level, and HBV serological markers were regularly measured during pregnancy and at approximately 6 weeks, 12 weeks, 24 weeks, 36 weeks, and 48 weeks postpartum. RESULTS: A total of 417 patients were enrolled, including 303 in the NA intervention group and 114 in the non-intervention group. The incidence rates of postpartum hepatitis flares in both groups were higher than that of during pregnancy (45.7% vs 10.9%, p < 0.001; 41.2% vs 17.7%, p < 0.001). The second trimester was the peak of the incidence of flares during pregnancy and the incidence peak of postpartum flares was about 6 weeks postpartum. A total of 98% (145/148) of postpartum flares occurred within 24 weeks postpartum. After drug cessation, the incidence rate of flares was 34.1% (44/129). CONCLUSION: In pregnant chronic HBV carriers, a certain proportion of hepatitis flares occurred during pregnancy and postpartum regardless of whether NA intervention was used, and the incidence of postpartum flares (44.6%) was significantly higher than that (12.8%) of during pregnancy. The flare incidence peaked at approximately 6 weeks postpartum, which may be the time period suitable for treatment. Since 98% of postpartum flares occurred within 24 weeks postpartum, the follow-up after drug cessation should be at least 24 weeks postpartum. Frontiers Media S.A. 2022-10-13 /pmc/articles/PMC9606458/ /pubmed/36311697 http://dx.doi.org/10.3389/fimmu.2022.1031291 Text en Copyright © 2022 Wang, Song, Lin, Lu, Zheng, Ma, Ren, Zheng and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Wang, Xiaoxiao Song, Aixin Lin, Xiao Lu, Junfeng Zheng, Sujun Ma, Lina Ren, Shan Zheng, Yanhong Chen, Xinyue Clinical characteristics of hepatitis flares during pregnancy and postpartum in Chinese chronic hepatitis B virus carriers—a prospective cohort study of 417 cases |
title | Clinical characteristics of hepatitis flares during pregnancy and postpartum in Chinese chronic hepatitis B virus carriers—a prospective cohort study of 417 cases |
title_full | Clinical characteristics of hepatitis flares during pregnancy and postpartum in Chinese chronic hepatitis B virus carriers—a prospective cohort study of 417 cases |
title_fullStr | Clinical characteristics of hepatitis flares during pregnancy and postpartum in Chinese chronic hepatitis B virus carriers—a prospective cohort study of 417 cases |
title_full_unstemmed | Clinical characteristics of hepatitis flares during pregnancy and postpartum in Chinese chronic hepatitis B virus carriers—a prospective cohort study of 417 cases |
title_short | Clinical characteristics of hepatitis flares during pregnancy and postpartum in Chinese chronic hepatitis B virus carriers—a prospective cohort study of 417 cases |
title_sort | clinical characteristics of hepatitis flares during pregnancy and postpartum in chinese chronic hepatitis b virus carriers—a prospective cohort study of 417 cases |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606458/ https://www.ncbi.nlm.nih.gov/pubmed/36311697 http://dx.doi.org/10.3389/fimmu.2022.1031291 |
work_keys_str_mv | AT wangxiaoxiao clinicalcharacteristicsofhepatitisflaresduringpregnancyandpostpartuminchinesechronichepatitisbviruscarriersaprospectivecohortstudyof417cases AT songaixin clinicalcharacteristicsofhepatitisflaresduringpregnancyandpostpartuminchinesechronichepatitisbviruscarriersaprospectivecohortstudyof417cases AT linxiao clinicalcharacteristicsofhepatitisflaresduringpregnancyandpostpartuminchinesechronichepatitisbviruscarriersaprospectivecohortstudyof417cases AT lujunfeng clinicalcharacteristicsofhepatitisflaresduringpregnancyandpostpartuminchinesechronichepatitisbviruscarriersaprospectivecohortstudyof417cases AT zhengsujun clinicalcharacteristicsofhepatitisflaresduringpregnancyandpostpartuminchinesechronichepatitisbviruscarriersaprospectivecohortstudyof417cases AT malina clinicalcharacteristicsofhepatitisflaresduringpregnancyandpostpartuminchinesechronichepatitisbviruscarriersaprospectivecohortstudyof417cases AT renshan clinicalcharacteristicsofhepatitisflaresduringpregnancyandpostpartuminchinesechronichepatitisbviruscarriersaprospectivecohortstudyof417cases AT zhengyanhong clinicalcharacteristicsofhepatitisflaresduringpregnancyandpostpartuminchinesechronichepatitisbviruscarriersaprospectivecohortstudyof417cases AT chenxinyue clinicalcharacteristicsofhepatitisflaresduringpregnancyandpostpartuminchinesechronichepatitisbviruscarriersaprospectivecohortstudyof417cases |